SMIM9: A Potential Drug Target and Biomarker (G100132963)
SMIM9: A Potential Drug Target and Biomarker
Small molecule inhibitors of metal ion channels (SMIMs) have been identified as potential drug targets in various diseases, including neurodegenerative disorders, pain, and cardiovascular diseases. SMIMs are a novel family of proteins that play a crucial role in cellular signaling, and their dysfunction has been implicated in a wide range of diseases. In this article, we will discuss the potential drug target and biomarker of SMIM9, and its implications for human health.
Potential Drug Target: SMIM9
SMIM9 is a member of the SMIM family, which includes several similar proteins that play a critical role in intracellular signaling. These proteins are involved in a wide range of cellular processes, including cell signaling, cell division, and neurotransmission. SMIM9 is expressed in various tissues and cells, including neurons, glial cells, and immune cells.
SMIM9 has been shown to play a crucial role in pain perception and neurodegenerative disorders. For example, studies have shown that SMIM9 is involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. SMIM9 has also been shown to play a role in pain perception, with altered levels of SMIM9 being associated with increased pain sensitivity in animals.
Potential Biomarker
SMIM9 is also a potential biomarker for a variety of diseases. For example, altered levels of SMIM9 have been shown to be associated with increased risk of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and other forms of dementia. Additionally, studies have shown that SMIM9 levels are altered in various psychiatric disorders, including major depressive disorder and anxiety disorders.
SMIM9 is also a potential biomarker for cancer, as altered levels of SMIM9 have been shown to be associated with increased cancer risk. Additionally, SMIM9 has been shown to play a role in the development and progression of various diseases, including cardiovascular disease and diabetes.
Conclusion
SMIM9 is a protein that has the potential to be a drug target and biomarker for a variety of diseases. Its involvement in cellular signaling and its association with various diseases make it an attractive target for drug development. Further research is needed to fully understand the role of SMIM9 in disease and its potential as a drug and biomarker.
Protein Name: Small Integral Membrane Protein 9
More Common Targets
SMKR1 | SMLR1 | SMN1 | SMN2 | SMNDC1 | SMO | SMOC1 | SMOC2 | SMOX | SMPD1 | SMPD2 | SMPD3 | SMPD4 | SMPD4BP | SMPD4P1 | SMPD5 | SMPDL3A | SMPDL3B | SMPX | SMR3A | SMR3B | SMS | SMTN | SMTNL1 | SMTNL2 | SMU1 | SMUG1 | SMURF1 | SMURF2 | SMURF2P1-LRRC37BP1 | SMYD1 | SMYD2 | SMYD3 | SMYD4 | SMYD5 | SNAI1 | SNAI2 | SNAI3 | SNAI3-AS1 | SNAP23 | SNAP25 | SNAP25-AS1 | SNAP29 | SNAP47 | SNAP91 | SNAPc complex | SNAPC1 | SNAPC2 | SNAPC3 | SNAPC4 | SNAPC5 | SNAPIN | SNAR-A1 | SNAR-A2 | SNAR-A3 | SNAR-B1 | SNAR-B2 | SNAR-C1 | SNAR-C3 | SNAR-D | SNAR-E | SNAR-G2 | SNAR-H | SNAR-I | SNARE complex | SNARP complex | SNCA | SNCA-AS1 | SNCAIP | SNCB | SNCG | SND1 | SND1-IT1 | SNED1 | SNF8 | SNF8P1 | SNHG1 | SNHG10 | SNHG11 | SNHG12 | SNHG14 | SNHG15 | SNHG16 | SNHG17 | SNHG18 | SNHG19 | SNHG20 | SNHG22 | SNHG25 | SNHG29 | SNHG3 | SNHG31 | SNHG32 | SNHG4 | SNHG5 | SNHG6 | SNHG7 | SNHG8 | SNHG9 | SNIP1